Veltuzumab is a monoclonal antibody (targeted at CD20) which is being investigated for the treatment of non-Hodgkin's lymphoma.

[1][2] As of December 2011[update], it is undergoing Phase I/II clinical trials.

[5] In August 2015 the US FDA granted it orphan drug status for immune thrombocytopenia (ITP).

[6] A phase II trial is planned to run for 5 years.

You can help Wikipedia by expanding it.This antineoplastic or immunomodulatory drug article is a stub.